Moreover, combination therapies including anti-TIGIT and anti-PD-L1 synergize to enhance cytolytic CD8+ T cell activity73,74 which could be used to target ovarian tumors of the infiltrated subtype to alleviate exhaustion and immunosuppression. Here, CD8A is linked to ovarian neoplasm.